查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1136916

全球傷口護理生物製品市場-2022-2029

Global Wound Care Biologics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

傷口護理生物製劑市場的增長受到燒傷發病率上升、傷口護理生物製劑在損傷治療中越來越多的採用、老年人口不斷增加以及研發活動的推動。

糖尿病患病率上升預計將推動市場增長

預計糖尿病和燒傷等疾病發病率的上升將在預測期內提振市場。根據 2022 年 5 月發表在 Star Pearls 上的一篇文章，全球糖尿病足潰瘍的年發病率在 910 萬至 2610 萬之間。大約 15-25% 的糖尿病患者在其一生中會患上糖尿病足潰瘍。新診斷的糖尿病患者逐年增加，糖尿病足潰瘍的發病率也在上升。糖尿病足潰瘍最常見於 45 歲以上的糖尿病患者，但可發生在任何年齡。在糖尿病患者中，腿部和下背部的小血管發生嚴重的動脈硬化，引起血管紊亂，這也是糖尿病足部感染的原因之一。在糖尿病足感染中，傷口供血不足會減緩癒合並最終導致壞死和壞疽。由於這些疾病的增加，全球對用於傷口護理的生物製劑的需求正在增加。

此外，市場參與者正在採取各種策略，例如合作夥伴關係和產品發布。例如，2021 年 1 月，Integra Life Sciences 收購了 ACell, Inc.。此次收購使 Integra 能夠提供更全面、更複雜的傷口管理解決方案。

高昂的傷口護理成本阻礙了市場增長

但是，預計所有傷口的醫療保健費用在 282 億美元到 967 億美元之間，包括感染控制費用，其中手術傷口和糖尿病潰瘍是最昂貴的。此外，門診費用（9.8-357 億美元）高於住院費用（5.0-243 億美元），這可能是由於門診傷口護理的增加。這些因素限制了市場增長。

COVID-19 影響分析

COVID-19 的出現對全球傷口護理生物製劑市場產生了相當大的影響。通常，醫護人員每周至少一次通過評估傷口進展、清創和應用 CTP（皮膚替代品）來治療慢性傷口。醫院門診部的傷口診所一直是治療這些傷口的主要護理點。然而，這些設施中有許多在最初的 COVID-19 爆發期間關閉，導致許多患有慢性傷口的患者看不到或治療較晚。這對傷口護理市場產生了負面影響。

由於正在進行的臨床試驗的延遲或取消、行業關閉以及政府法規將重點轉移到控制冠狀病毒疾病上，一些市場參與者正在放慢新療法的開發。面臨困難。

此外，市場參與者正在努力通過採用收購和新產品發布等市場策略來擴展業務。同樣在 2020 年 11 月，史賽克公司收購了 Wright Medical Group N.V.，這是一家專注於四肢和生物製品的全球醫療器械公司。

全球傷口護理生物製品市場報告將提供對大約 65 多個市場數據表、65 多個圖表和 200 多頁（大約）的訪問。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 燒傷發生率增加
      • 加大研發力度
    • 約束因素
      • 用於傷口護理的生物製劑成本高
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 活的皮膚替代品
    • 合成皮膚移植物
    • 沿著嫁接
    • 異種移植
  • 外部代理

第 8 章按傷口類型

  • 慢性傷口
    • 糖尿病足潰瘍
    • 靜脈性腿部潰瘍
    • 壓瘡
  • 急性傷口
  • 手術傷口
  • 燒傷
  • 其他

第 9 章，最終用戶

  • 醫院
  • 燃燒中心
  • 門診手術中心
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 12 章公司簡介

  • Organogenesis Inc.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Integra Lifesciences
  • Smith and Nephew
  • Acell Inc.
  • Osiris Therapeutics
  • Avita Medical
  • Solsys Medical
  • Generex Biotechnology
  • Mimedx
  • Skye Biologics

第 13 章全球傷口護理生物製品市場-DataM

簡介目錄
Product Code: DMMD742

Market Overview

Wound care biologics market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 6.2% during the forecast period (2022-2029).

Wound care biologic therapies promote the re-establishment of the intrinsic repair mechanisms and application of these active biological agents, including plant-derived active biomolecules, which exhibit antimicrobial, antioxidant, or anti-inflammatory attributes. Biologic dressings help to prevent evaporative heat loss, water loss, protein and electrolyte loss, and contamination.

Market Dynamics

The wound care biologics market growth is driven by the rise in the incidence of burn injuries, the rising adoption of wound care biologics for treating injuries, the increase in the geriatric population, and research and development activities.

The rising prevalence of diabetes diseases is expected to drive the market growth

The rising incidence of diseases, such as diabetes and burn injuries, is expected to boost the market over the forecast period. As per the article published in Star Pearls in May 2022, the annual incidence of diabetic foot ulcers worldwide is between 9.1 to 26.1 million. Around 15 to 25% of patients with diabetes mellitus will develop a diabetic foot ulcer in their lifetime. As the number of newly diagnosed diabetics is increasing annually, the incidence of a diabetic foot ulcers is also bound to rise. Diabetic foot ulcers can arise at any age despite being most prevalent in ages 45 and over in patients with diabetes mellitus. Patients suffering from diabetes mellitus develop intense atherosclerosis of the small blood vessels in the legs and feet, directing to vascular compromise, which is another cause of diabetic foot infections. Healing is delayed, eventually leading to necrosis and gangrene because blood cannot reach the wound. The rising disease incidence leads to increasing demand for wound care biologics worldwide.

In addition, the market players are adopting different strategies, such as collaboration and product launches. For instance, in January 2021, Integra Lifesciences acquired ACell, Inc. This acquisition enabled Integra to deliver more comprehensive and complex wound management solutions.

The high cost of wound care will hamper the growth of the market

However, healthcare cost predictions for all wounds ranged from $28.2 to $96.7 billion, including costs for infection management, in which surgical wounds and diabetic ulcers were the most expensive to treat. Moreover, outpatient costs ($9.8-$35.7 billion) are higher than inpatient costs ($5.0-$24.3 billion), possibly due to increased outpatient wound treatments. These factors are limiting the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global wound care biologics market. Mainly, healthcare professionals treat chronic wounds at least once a week to assess the progress of the wound, provide debridement or apply CTPs (skin substitutes). The hospital outpatient department wound clinics had the primary care site to treat these wounds. Still, with the closing of many of these facilities during the initial COVID-19 rise, many patients with chronic wounds were not seen or delaying treatment.. This negatively affected the wound care market.

Some market players have faced difficulties developing new treatments because of the delay or cancellation of ongoing clinical trials and government restrictions to shut down the industries or to move the focus on managing the coronavirus infection.

In addition, the market players were engaged in expanding the business by adopting the market strategies such as acquisition or new product launches. Also, in November 2020, Stryker Corporation acquired Wright Medical Group N.V., a global medical devices company concentrated on extremities and biologics.

Segment Analysis

The chronic wounds segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The chronic wounds segment is expected to boost the market over the forecast period. Chronic wounds construct significant problems for patients. They are hurting and tender. Wounds often fatigue and emit odors, and involved dressings are often evident. Unprotected by an unbroken skin envelope, these wounds can be retraumatized and improvement in size. They may design an infection directed to sepsis and amputation. Patients with diabetes and obesity are at increased risk of developing chronic wounds. The vast majority of people who have a long open wound usually also have other significant health conditions. The simultaneous presence of a variety of chronic diseases is called comorbidity. Chronic wounds are usually confused by comorbidities, making it challenging to track chronic wounds as a disease.

As per the Wound Infection Clinical Practice data in 2022, the Standard clinical microbiology laboratory released outcomes that only supply information regarding a small subset of the bacterial species present, mainly in chronic wounds. If infection with fungi, mycobacteria or anaerobic bacteria is presumed, for example, following environmental contamination of a wound, this should be precisely requested or concerned with a microbiologist as these organisms need further examinations and processing. The increasing incidence and advanced diagnostics for chronic wounds drive the wound care biologic market.

Geographical Analysis

North America region holds the largest market share of the global Wound Care Biologics market

North America dominates the market for wound care biologics and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increasing geriatric population, technological advancement, and growing research and development activities. According to the article published in Advance in Wound Care in May 2021, chronic wounds are mostly seen in the elderly. In the United States, 3% of the population aged 65 has open wounds. By 2060, the U.S. government evaluates that the elderly population will be over 77 million, signifying that chronic wounds will resume being an increasingly constant concern in these people. Around the United States, 2% of the entire population is assessed to be impacted by chronic wounds.

In addition, the market players are applying market strategies such as collaboration and new product launches. For instance, in June 2021, MIMEDX received approval from the Japanese Ministry of Health, Labour and Welfare for the commercialization of Epifix in Japan. In April 2021, Kerecis presented its Kerecis Omega3 GraftGuide, an intact fish skin that uniquely manages the challenges of burn healing.

Competitive Landscape

The wound care biologics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Organogenesis Inc., Integra Lifesciences, Smith and Nephew, Acell Inc., Osiris Therapeutics, Avita Medical, Solsys Medical, Generex Biotechnology, Mimedx, Skye Biologics among others. The major players are adopting several growth strategies, such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the wound care biologics market globally.

For instance,

  • In July 2022, Biologics Company Tides Medical introduced Artacent AC, a tri-layer skin graft designed to treat complex or difficult-to-treat wounds.
  • In May 2022, MIMEDX received USD 4.6 million in awards department of defense to evaluate PURION-processed Dehydrated Human Amnion Chorion Membrane (DHACM) to advance the treatment of combat casualty wounds and burns.

Zax Healthcare

Overview:

Organogenesis Inc. is a medicine company founded in 1985 and headquartered in the United States. The company offers a portfolio of acellular and bioactive biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

Product Portfolio:

PuraPly: It is an antimicrobial wound matrix is an FDA 510(k)-cleared Class II medical device used for the management of various types of wounds, including acute and chronic wound types, such as pressure ulcers, partial and full-thickness wounds, venous ulcers, chronic vascular ulcers, diabetic ulcers, tunneled/undermined wounds, draining wounds, trauma wounds, and first- and second-degree burns.

The global wound care biologics market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising incidence of burn injuries
      • 4.1.1.2. Increase research and development activities
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of wound care biologic
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Biological Skin Substitutes*
    • 7.2.1. Synthetic Skin Grafts
    • 7.2.2. Allografts
    • 7.2.3. Xenografts
    • 7.2.4. Introduction
    • 7.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Topical Agents

8. By Wound Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 8.1.2. Market Attractiveness Index, By Wound Type
  • 8.2. Chronic Wounds*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Diabetic Foot Ulcers
    • 8.2.4. Venous Leg Ulcers
    • 8.2.5. Pressure Ulcers
  • 8.3. Acute Wounds
  • 8.4. Surgical Wounds
  • 8.5. Burns
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Burn Centers
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wound Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Organogenesis Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Integra Lifesciences
  • 12.3. Smith and Nephew
  • 12.4. Acell Inc.
  • 12.5. Osiris Therapeutics
  • 12.6. Avita Medical
  • 12.7. Solsys Medical
  • 12.8. Generex Biotechnology
  • 12.9. Mimedx
  • 12.10. Skye Biologics

LIST NOT EXHAUSTIVE

13. Global Wound Care Biologics market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us